IRLAB Therapeutics
5.11.2021 08:07:05 CET | ACCESS Newswire | Press release
GOTHENBURG, SE / ACCESSWIRE / November 5, 2021 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)
IRLAB Therapeutics AB (publ) will publish the interim report for the period January - September 2021 on Wednesday 10 November 2021 at 07:45 CET. A conference call will be held the same day starting at 10:30 CET, where CEO Nicholas Waters and CFO Viktor Siewertz will present the report. The presentation will be held in Swedish and will be followed by a Q&A session.
For those who wish to participate in the conference call, please dial:
SE + 46 850 558 373 or
UK + 44 333 300 9030
It is also possible to follow and listen to the presentation live on https://tv.streamfabriken.com/irlab-q3-2021
The presentation material will be available in Swedish and published in connection with the conference call on www.irlab.se , where the recorded version of the webcast will be available afterwards.
For more information
Åsa Hillsten, Head of IR & Corporate Communications
Mobile: +46 700 81 81 17
E-mail: asa.hillsten@irlab.se
About IRLAB
IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson's disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), have completed Phase IIa studies and are designed to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PDP) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (the Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS)-related disorders where large and growing medical needs exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. The project portfolio comprises a combination of the fully-funded mesdopetam program, run in collaboration with global partner Ipsen, as well as innovative in-house programs from preclinical to Phase IIb. IRLAB is listed on Nasdaq Stockholm Main Market. More information on www.irlab.se .
Attachments
Invitation to the presentation of IRLAB´s Interim report January - September 2021
SOURCE: IRLAB Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/671344/Invitation-to-the-Presentation-of-IRLABs-Interim-Report-January-September-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
ePropelled to Showcase Next Generation Electric Propulsion, Software Innovation and Autonomous Systems Capabilities at Farnborough International Airshow 202617.7.2026 17:00:00 CEST | Press release
Meet the ePropelled team in Hall 2, Stand 2039, on the New Hampshire Mission Pavilion FARNBOROUGH, UK / ACCESS Newswire / July 17, 2026 / ePropelled, a leading global provider of smart propulsion solutions and energy management systems, will exhibit at the Farnborough International Airshow 2026, showcasing its latest innovations for aerospace, defense and uncrewed vehicle applications. Visitors to Hall 2, Stand 2039 on the New Hampshire Mission Pavilion will have the opportunity to meet the ePropelled team and learn about a range of exciting developments, including new product launches, software innovations, technology updates and exclusive previews of next-generation solutions currently in development. With autonomy, electrification and intelligent mobility driving the future of aerospace and defence, ePropelled continues to develop advanced propulsion, power management and software technologies that enhance performance, efficiency and mission capability across air, land and maritime
As the UK Backs Life Sciences and Advanced Manufacturing, US PMO Firm MustardSeed Moves In to Help Deliver It16.7.2026 11:00:00 CEST | Press release
The expansion reflects growing client demand for embedded programme management support across highly regulated industries. WEST CHESTER, PA AND MANCHESTER, UK / ACCESS Newswire / July 16, 2026 / The UK Government's 2025 Modern Industrial Strategy has put life sciences, advanced manufacturing, defence, and clean energy at the centre of Britain's growth agenda. MustardSeed, a US-based programme management and PMO consultancy, is launching UK operations to help organisations in those sectors deliver on that ambition. The 2025 Modern Industrial Strategy names life sciences and advanced manufacturing among its eight priority sectors, alongside defence and clean energy. These are industries defined by complex, regulated, multi-stakeholder programmes where disciplined execution directly determines commercial and operational outcomes. MustardSeed, headquartered in West Chester, Pennsylvania, has built its practice around delivering that execution. The firm announced today the launch of its UK
Akkodis Recognized in the 2026 Gartner(R) Emerging Market Quadrant for Physical AI Services16.7.2026 06:45:00 CEST | Press release
Akkodis continues to advance full-stack engineering expertise and industrial-grade AI deployments. ZURICH, SWITZERLAND / ACCESS Newswire / July 16, 2026 / Akkodis, a global digital engineering consulting company and part of the Adecco Group, has been recognized as a Specialist in the Gartner Emerging Market Quadrant for Physical AI Services (PAIS), published on June 8, 2026. Physical AI services address the complex challenge of designing, developing, deploying and operating AI‑enabled physical systems - such as robots, autonomous systems including, vehicles, drones and industrial infrastructure - in real‑world environments. The Gartner report states "The PAIS market is moving from exploratory experimentation toward operational reliability at scale. This trend is driven by mounting labor constraints, safety requirements, infrastructure modernization and advances in AI, simulation and automation technologies." Full‑stack Physical AI capabilities with real‑world impact and measurable outc
Loar Holdings Inc. Announces Date and Time for Second Quarter 2026 Earnings and Conference Call15.7.2026 22:15:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / July 15, 2026 / Loar Holdings Inc. (NYSE:LOAR) will report Q2 2026 earnings before the market opens on Thursday, August 6, 2026. A conference call will follow at 11:00a.m. Eastern Time. To participate in the call telephonically please dial +1 877-407-0670 / +1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website: https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact Ian McKillop Loar Holdings Inc. Investor Relations IR@loargro
Fermi Outlines Strategic Rationale for Upsized $431 Million Convertible Notes Offering15.7.2026 14:30:00 CEST | Press release
Flexible convertible structure with shareholder-friendly capped call minimizes dilution Proceeds strengthen liquidity in midst of customer and partner negotiations and preserve Fermi's speed-to-power advantage Attractive five-year cost of capital provides run room to advance multiple commercial tracks in parallel DALLAS, TX / ACCESS Newswire / July 15, 2026 / Fermi Inc. (Nasdaq:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), outlined today the strategic rationale for its recently closed and upsized offering of $431.25 million aggregate principal amount of 5.00% Convertible Senior Notes due 2031 (the "Notes"), which included the exercise in full of the initial purchasers' 13-day option to purchase up to an additional $56.25 million aggregate principal amount of Notes. The Notes are intended to strengthen Fermi's balance sheet, enhance liquidity, and support continued execution of Project Matador as the Company advances tenant, strategic partnership, and power-de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom